BALTIMORE, April 3, 2008 /PRNewswire/ -- Alba Therapeutics Corporation
today announced the appointment of Bruce A. Peacock as its Chief Executive
Officer (CEO) and a member of its Board of Directors. Mr. Peacock is a
Venture Partner with SV Life Sciences Advisors, LLC. Previously, he served
as the CEO or was a member of the senior management team for several
successful entrepreneurial healthcare companies operating in therapeutic,
diagnostic and service areas including The Little Clinic, Adolor
Corporation, Orthovita, Inc., Cephalon, Inc., and Centocor, Inc.
"Mr. Peacock brings a wealth of experience and leadership with a proven
track record of success," said Dan Janney of Alba's Board of Directors.
"His experience in leading successful research and development and
commercial infrastructures will be invaluable to Alba."
In a related announcement, Blake M. Paterson, MD, Alba's CEO and Co-
Founder since its inception in 2004, has left the company to pursue other
advisory and entrepreneurial interests. Since founding the Company, Dr.
Paterson has raised over $40 million in funding for the Company and under
his direction and leadership Alba has grown into a thriving Baltimore
biotechnology company with 45 employees in its headquarters at the
University of Maryland BioPark. This growth has led to the achievement of
significant milestones including successful proof-of-concept for Alba's
clinical candidate, larazotide acetate in celiac disease and the
establishment of a licensing and collaboration agreement worth up to $325
million with Shire Pharmaceuticals.
"The addition of Mr. Peacock to the Alba management team will position
the Company for the next level of financial and developmental success. I
look forward to continuing to support the Alba team in their endeavors, as
founder and past president," said Dr. Blake Paterson.
Dr. Lutz Giebel of Alba's Board of Directors commented, "We are
extremely grateful to Blake for his commitment, dedication, vision and
passion for the broad technology platform Alba has created and for helping
to create medicines for patients with unmet medical needs. We will continue
to count on his valuable perspective as the Company moves forward."
About Alba
Alba Therapeutics Corporation is a privately held, clinical-stage
biopharmaceutical Company focused on the discovery, development, and
commercialization of therapies to treat autoimmune and inflammatory
diseases and is based in Baltimore, Maryland. Alba's technology platform is
based upon a key pathway that regulates the assembly and disassembly of
tight junctions in cell barriers throughout the body. As a result of its
unique technology platform, Alba is a leader in mucosal biology and has
developed a pipeline of innovative therapeutic candidates that has the
potential to modify the course of disease and significantly improve upon
existing treatments for a wide range of diseases such as Celiac disease,
Crohn's disease, and Asthma/COPD or acute lung injury.
Contact: Wendy Perrow, MBA
Phone: 410-878-9850
E-mail: info@albatherapeutics.com
Web site: http://www.albatherapeutics.com
SOURCE Alba Therapeutics Corporation
 back to top
Related links:
http://www.albatherapeutics.com
CONTACT:
Wendy Perrow, MBA of Alba Therapeutics
Corporation, +1-410-878-9850, info@albatherapeutics.com
|
